Driving Impaired Clinical Trial
Official title:
Cannabis Consumption and Driving Impairment Assessment on a Closed Course
In a true experiment, roughly 300 volunteer participants will smoke active cannabis, a corresponding placebo, or no substance at all (control). Next, participants will complete a drive test and then be observed by actual California Highway Patrol (CHP) officers who will attempt to classify participants as impaired or unimpaired. CHP Officers will evaluate participants in the context of driving (i.e., while following participants in an actual patrol car), as part of a roadside behavioral assessment (i.e., the Advanced Roadside Impaired Driving Enforcement, or ARIDE, battery, which includes Standardized Field Sobriety Tests, or SFSTs), and as part of a Drug Recognition Expert (DRE) evaluation conducted indoors.
Status | Recruiting |
Enrollment | 300 |
Est. completion date | December 31, 2024 |
Est. primary completion date | December 31, 2024 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 21 Years to 55 Years |
Eligibility | Inclusion Criteria: - Possessing a valid California driver's license - Cannabis use in the past six months - Willing and able to abstain from alcohol, cannabis, and other recreational drugs for 24 hours prior to scheduled participation - Willing and able to avoid driving and operating heavy machinery for at least four hours after participation - Residence within approximately 15 miles of the study site - Possessing the capacity to provide informed consent Exclusion Criteria: - Completion of a roadside sobriety test during the previous 12 months - Physical or psychological conditions that can be exacerbated by cannabis use, or for which cannabis use is contraindicated - Potential presence of Cannabis Use Disorder as assessed by a modified version of the Cannabis Use Disorder Identification Test - Potential presence of Substance Use Disorder as assessed by a modified version of the Drug Abuse Screening Test - Pregnancy or breastfeeding reported - Unwillingness to be transported by taxi - Having been convicted of Driving Under the Influence (DUI) within five years prior to scheduled participation - Parole or probation status - One or more felony convictions on record involving aggressive or dangerous criminal activity - Any of the following at the time of the experimental session: breath alcohol content of .01% or greater; positive pregnancy test; cannabis consumption considered unsafe following medical checkup by the study nurse; or driving test behavior considered hazardous by the driving examiner |
Country | Name | City | State |
---|---|---|---|
United States | California Department of Motor Vehicles Headquarters | Sacramento | California |
Lead Sponsor | Collaborator |
---|---|
Bayliss J. Camp, PhD |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Modified Driving Performance Examination (MDPE) | The MDPE driving test, developed for this study, is administered once per participant per experimental session. It occurs after the assigned intervention (i.e., drug administration) and it is primarily scored dichotomously (pass versus fail). | Conducted an average of 35 minutes after the assigned intervention is completed. | |
Primary | Advanced Roadside Impaired Driving Enforcement (ARIDE) battery | The ARIDE battery is not a scale but a series of roadside behavioral assessments used by law enforcement officers to help them detect impaired driving: (1) pulse check, (2) Horizontal Gaze Nystagmus or HGN, (3) a test of distinct and sustained nystagmus, (4) vertical nystagmus, (5) lack of convergence test, (6) a check to see if eyes are bloodshot or watery, (7) Modified Romberg Balance Test, (8) Walk and Turn Test or WAT, (9) One Leg Stand Test or OLS, and some additional observations.
The ARIDE battery occurs once per participant following the Modified Driving Performance Examination. The ARIDE battery is scored overall as pass versus fail by the officer conducting the test (in real-time). |
Conducted an average of 65 minutes after the assigned intervention is completed. | |
Primary | Drug Recognition Expert (DRE) evaluation | The DRE evaluation is designed to help law enforcement officers identify whether an individual is generally impaired and, if so, which class of substance caused the impairment.
The DRE evaluation occurs once per participant, following the ARIDE battery. It is scored by the officer conducting it in real-time as a judgment about state of impairment (impaired versus unimpaired), and, in the case of impairment, a judgment about the class of substance. |
Conducted an average of 90 minutes after the assigned intervention is completed. | |
Secondary | First blood draw (baseline) | The first blood sample is collected at baseline (after consent procedures and a medical checkup), roughly 25 minutes into the experimental session. This is before the assigned intervention (i.e., drug administration) and before any of the primary outcome measures occurs.
All samples will undergo toxicological analyses to assess blood concentrations (in nanograms per milliliter) of cannabinoids, as well as the presence of other drugs (opioids, benzodiazepines, and stimulants). |
Conducted 15 minutes before the assigned intervention. | |
Secondary | Second blood draw (change from baseline) | The second blood sample is collected immediately after the assigned intervention (i.e., drug administration), around the time that THC concentration is expected to be at its peak.
Most samples will undergo toxicological analyses to assess blood concentrations (in nanograms per milliliter) of cannabinoids and these results will be compared to those of the first blood draw. In the case of control participants whose first sample did not reveal the presence of cannabinoids, no further analyses will be conducted. |
Conducted immediately after the assigned intervention is completed. | |
Secondary | Third blood draw (change from baseline and second blood draw) | The third blood sample is collected after the Advanced Roadside Impaired Driving Enforcement (ARIDE) battery and immediately before the Drug Recognition Expert (DRE) evaluation.
Most samples will undergo toxicological analyses to assess blood concentrations (in nanograms per milliliter) of cannabinoids and these results will be compared to those of the first and second blood draws. In the case of control participants whose first sample did not reveal the presence of cannabinoids, no further analyses will be conducted. |
Conducted an average of 85 minutes after the assigned intervention is completed. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Enrolling by invitation |
NCT05537116 -
Evaluation of an Interactive Mobile Phone-Based Brief Intervention to Reduce Substance-Impaired Driving
|
N/A | |
Completed |
NCT03169855 -
Validation of Mesopic and Photopic Contrast Vision Tests With Respect to Nighttime Driving Ability
|
||
Recruiting |
NCT06111989 -
Fitness to Drive Among Stroke Patients
|
||
Completed |
NCT04587609 -
Reducing Cell Phone Use While Driving Among High Risk UBI Auto Policy Holders
|
N/A | |
Completed |
NCT03656029 -
Dose-response of Cannabis and Driving
|
Phase 2 | |
Completed |
NCT04330196 -
Effect of Postprandial Hyperinsulinaemic Hypoglycaemia on Driving Performance.
|
N/A | |
Completed |
NCT03353922 -
Driving Simulation to Assess Non-Sedative Effects of Tolperisone
|
Phase 1 | |
Completed |
NCT04948385 -
Driving Performance After Deep Sedation for Outpatient Endoscopy
|
Phase 4 | |
Completed |
NCT03335735 -
Smartphone-paired Breathalyzers and Loss- and Gain-framed Texts for Reducing Drinking and Driving
|
N/A | |
Not yet recruiting |
NCT05703360 -
Effectiveness of AV-stimulation in Immersive VR to Improve Visual Perception and Driving Performance
|
N/A | |
Active, not recruiting |
NCT03581058 -
Neural Correlates of Driving and Cannabis
|
Phase 1 | |
Withdrawn |
NCT05273658 -
Effects of Cannabis/Alcohol on Driving Performance and Field Sobriety Tests
|
Phase 1/Phase 2 | |
Completed |
NCT04648735 -
Driving Evaluation and Fitness for Persons With Cognitive Impairments
|
N/A | |
Completed |
NCT03195608 -
Using Advanced Driver Assistance Systems (ADAS) as an Intervention Strategy for Drivers With Parkinson's Disease
|
N/A |